Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Vertex Pharmaceuticals Incorporated (VRTX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Sept. 30, 2015.
Market data for VRTX model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for VRTX.
Model is being retrained on a daily basis.
|% Held by Insiders||1.80%|
|% Held by Institutions||94.80%|
|EPS (last reported FY)||$0.80|
|EPS (last reported Q)||$0.54|
|EPS, estimated (last reported Q)||$0.28|
|Total revenues||$2 B|
|Net income||$0 B|